71 related articles for article (PubMed ID: 15521922)
21. Procarboxypeptidase U (TAFI) and the Thr325Ile proCPU polymorphism in patients with hereditary mucocutaneous hemorrhages.
Matus V; Willemse J; Quiroga T; Goycoolea M; Aranda E; Panes O; Pereira J; Hendriks D; Mezzano D
Clin Chim Acta; 2009 Mar; 401(1-2):158-61. PubMed ID: 19038242
[TBL] [Abstract][Full Text] [Related]
22. The 1040C/T polymorphism influencing thermal stability and activity of thrombin activatable fibrinolysis inhibitor is associated with risk for oral cancer.
Vairaktaris E; Yapijakis C; Nkenke E; Vassiliou S; Vylliotis A; Nixon AM; Derka S; Ragos V; Spyridonidou S; Tsigris C; Neukam FW; Patsouris E
Am J Hematol; 2007 Nov; 82(11):1010-2. PubMed ID: 17636471
[TBL] [Abstract][Full Text] [Related]
23. Development of a genotype 325-specific proCPU/TAFI ELISA.
Gils A; Alessi MC; Brouwers E; Peeters M; Marx P; Leurs J; Bouma B; Hendriks D; Juhan-Vague I; Declerck PJ
Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1122-7. PubMed ID: 12730084
[TBL] [Abstract][Full Text] [Related]
24. Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level.
Santamaría A; Martínez-Rubio A; Borrell M; Mateo J; Ortín R; Fontcuberta J
Haematologica; 2004 Jul; 89(7):880-1. PubMed ID: 15257950
[TBL] [Abstract][Full Text] [Related]
25. Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels.
Folkeringa N; Coppens M; Veeger NJ; Bom VJ; Middeldorp S; Hamulyak K; Prins MH; Büller HR; van der Meer J
Thromb Haemost; 2008 Jul; 100(1):38-44. PubMed ID: 18612536
[TBL] [Abstract][Full Text] [Related]
26. Association between polymorphisms in the flanking region of the TAFI gene and atherosclerotic cerebral infarction in a Chinese population.
Li Y; Zeng Z; Zhao J; Ma G; Cui L; Tao H; Lin Z; Chen Y; Zhao B; Chen Y; Li K
Lipids Health Dis; 2014 May; 13():80. PubMed ID: 24886076
[TBL] [Abstract][Full Text] [Related]
27. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis.
Ricart JM; Ramón LA; Vayá A; España F; Santaolaria ML; Todolí J; Castelló R; Fontcuberta J; Estellés A
Br J Haematol; 2008 May; 141(5):716-9. PubMed ID: 18341631
[TBL] [Abstract][Full Text] [Related]
28. Association between the Thr325Ile and Ala147Thr polymorphisms of the TAFI gene and the risk of venous thromboembolic disease.
Verdú J; Marco P; Benlloch S; Lucas J
Clin Appl Thromb Hemost; 2008 Oct; 14(4):494-5. PubMed ID: 18160566
[No Abstract] [Full Text] [Related]
29. Thrombin activatable fibrinolysis inhibitor (TAFI): a role in pre-eclampsia?
Dusse LM; Cooper AJ; Lwaleed BA
Clin Chim Acta; 2007 Mar; 378(1-2):1-6. PubMed ID: 17184758
[TBL] [Abstract][Full Text] [Related]
30. TAFI activity in coronary artery disease: a contribution to the current discussion on TAFI assays.
Schroeder V; Wilmer M; Buehler B; Kohler HP
Thromb Haemost; 2006 Aug; 96(2):236-7. PubMed ID: 16894472
[No Abstract] [Full Text] [Related]
31. [Microsatellite DNA polymorphism of adrenomedullin gene and atherosclerotic cerebral infarction].
Bi GR; Hai H; Bai LJ; Zhang HM; Zhou HJ
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Oct; 24(5):579-81. PubMed ID: 17922433
[TBL] [Abstract][Full Text] [Related]
32. Thrombin activatable fibrinolysis inhibitor in Behçet's disease.
Donmez A; Aksu K; Celik HA; Keser G; Cagirgan S; Omay SB; Inal V; Aydin HH; Tombuloglu M; Doganavsargil E
Thromb Res; 2005; 115(4):287-92. PubMed ID: 15668188
[TBL] [Abstract][Full Text] [Related]
33. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
Koutroubakis IE; Sfiridaki A; Tsiolakidou G; Coucoutsi C; Theodoropoulou A; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
[TBL] [Abstract][Full Text] [Related]
34. [Correlation of thrombospondin-1 G1678A polymorphism to stroke: a study in Chinese population].
Liu XN; Song L; Wang DW; Liao YH; Ma AQ; Zhu ZM; Zhao BR; Zhao JZ; Hui RT
Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(23):1959-62. PubMed ID: 15730804
[TBL] [Abstract][Full Text] [Related]
35. [Associations between Ser447Ter gene polymorphism of lipoprotein lipase and atherosclerotic cerebral infarction].
Guan GD; Xu E; Wang XJ; Xu YH; Qiu SD
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Oct; 23(5):519-22. PubMed ID: 17029199
[TBL] [Abstract][Full Text] [Related]
36. Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity.
Guven GS; Kiliçaslan A; Oz SG; Haznedaroglu IC; Kirazli S; Aslan D; Sözen T
Clin Appl Thromb Hemost; 2006 Jul; 12(3):364-8. PubMed ID: 16959692
[TBL] [Abstract][Full Text] [Related]
37. [The association of apolipoprotein B gene polymorphism with cerebral infarction with positive family history and its effect on plasma lipid levels].
Liu BQ; Zhang L; Yang QD; Liu YH; Hu ZY; Xu HW; DU XP; Xia J
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(47):3332-6. PubMed ID: 19257963
[TBL] [Abstract][Full Text] [Related]
38. Polymorphisms and vascular cognitive impairment after ischemic stroke.
Baum L; Chen X; Cheung WS; Cheung CK; Cheung LW; Chiu KF; Wen HM; Poon P; Woo KS; Ng HK; Wong KS
J Geriatr Psychiatry Neurol; 2007 Jun; 20(2):93-9. PubMed ID: 17548779
[TBL] [Abstract][Full Text] [Related]
39. [Thrombin activatable fibrinolysis inhibitor (TAFI) in allergic asthma patients].
Kemona-Chetnik I; Kowal K; Kucharewicz I; Pampuch A; Bodzenta-Lukaszyk A
Przegl Lek; 2006; 63(12):1281-5. PubMed ID: 17642140
[TBL] [Abstract][Full Text] [Related]
40. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact.
Frère C; Morange PE; Saut N; Tregouet DA; Grosley M; Beltran J; Juhan-Vague I; Alessi MC
Thromb Haemost; 2005 Aug; 94(2):373-9. PubMed ID: 16113828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
